×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
GNPX – genprex, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
GNPX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/24
07:00 am
gnpx
Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer
Medium
Report
Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer
11/19
07:38 am
gnpx
Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials [Yahoo! Finance]
High
Report
Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials [Yahoo! Finance]
11/19
07:00 am
gnpx
Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials
High
Report
Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials
11/18
07:32 am
gnpx
Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers [Yahoo! Finance]
High
Report
Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers [Yahoo! Finance]
11/18
07:00 am
gnpx
Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
High
Report
Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
11/4
07:00 am
gnpx
Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
High
Report
Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
10/28
11:19 am
gnpx
Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules
High
Report
Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules
10/28
07:00 am
gnpx
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
High
Report
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/26
08:01 am
gnpx
Form 8-K Genprex, Inc. For: Nov 25
Medium
Report
Form 8-K Genprex, Inc. For: Nov 25
11/21
04:46 pm
gnpx
Form 8-K Genprex, Inc. For: Nov 21
Medium
Report
Form 8-K Genprex, Inc. For: Nov 21
11/19
07:13 am
gnpx
Form 8-K Genprex, Inc. For: Nov 19
Medium
Report
Form 8-K Genprex, Inc. For: Nov 19
11/18
07:10 am
gnpx
Form 8-K Genprex, Inc. For: Nov 18
High
Report
Form 8-K Genprex, Inc. For: Nov 18
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/17
Form 424B5 Genprex, Inc.
228.6%
3/16 Form 3 Genprex, Inc. For: Mar 12 Filed by: Redman Michael Thomas 105.6%
11/19 Genprex Reports Positive Preclinical Data for the Treatment of Some of the Most Resistant Metastatic Lung Cancers 63.2%
1/23 Genprex, Inc. Prices $8,000,000 Common Stock Offering Priced At-The-Market 32.1%
2/11 Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes 26.8%
1/29 Independent Researchers Find Genprex’s TUSC2 May Be a Novel Target and Biomarker for Thyroid Cancer Therapy 24.4%
2/20 Form 8-K Genprex, Inc. For: Feb 19 22.0%
1/31 Form SC 13G Genprex, Inc. Filed by: INTRACOASTAL CAPITAL, LLC 18.3%
4/21 Form 8-K Genprex, Inc. For: Apr 15 18.2%
2/21 Genprex, Inc. Announces Closing of $17,500,000 Common Stock Offering At-The-Market and Without Warrants 14.2%
3/16 Form 3 Genprex, Inc. For: Mar 12 Filed by: Redman Michael Thomas 105.6%
11/19 Genprex Reports Positive Preclinical Data for the Treatment of Some of the Most Resistant Metastatic Lung Cancers 63.2%
1/23 Genprex, Inc. Prices $8,000,000 Common Stock Offering Priced At-The-Market 32.1%
2/11 Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes 26.8%
1/29 Independent Researchers Find Genprex’s TUSC2 May Be a Novel Target and Biomarker for Thyroid Cancer Therapy 24.4%
2/20 Form 8-K Genprex, Inc. For: Feb 19 22.0%
1/31 Form SC 13G Genprex, Inc. Filed by: INTRACOASTAL CAPITAL, LLC 18.3%
4/21 Form 8-K Genprex, Inc. For: Apr 15 18.2%
2/21 Genprex, Inc. Announces Closing of $17,500,000 Common Stock Offering At-The-Market and Without Warrants 14.2%
TOP News Decliners
11/20
Genprex Announces $1.26 Million Registered Direct Offering
-35.5%
1/23 Genprex Inc (NASDAQ: GNPX) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -34.3%
2/19 Form S-3MEF Genprex, Inc. -33.3%
11/22 Form 8-K Genprex, Inc. For: Nov 20 -15.3%
3/31 Form 3/A Genprex, Inc. For: Mar 18 Filed by: Wilson William R Jr. -9.8%
3/20 Form 3 Genprex, Inc. For: Mar 18 Filed by: Wilson William R Jr. -9.2%
1/21 Form 8-K Genprex, Inc. For: Jan 21 -8.7%
12/10 Form PRE 14A Genprex, Inc. For: Jan 27 -8.4%
10/4 Form S-3/A Genprex, Inc. -8.0%
3/3 Genprex to Present at the 2020 LD Micro Virtual Conference -7.5%
1/23 Genprex Inc (NASDAQ: GNPX) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -34.3%
2/19 Form S-3MEF Genprex, Inc. -33.3%
11/22 Form 8-K Genprex, Inc. For: Nov 20 -15.3%
3/31 Form 3/A Genprex, Inc. For: Mar 18 Filed by: Wilson William R Jr. -9.8%
3/20 Form 3 Genprex, Inc. For: Mar 18 Filed by: Wilson William R Jr. -9.2%
1/21 Form 8-K Genprex, Inc. For: Jan 21 -8.7%
12/10 Form PRE 14A Genprex, Inc. For: Jan 27 -8.4%
10/4 Form S-3/A Genprex, Inc. -8.0%
3/3 Genprex to Present at the 2020 LD Micro Virtual Conference -7.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: